Supplementary Tables 1, 2, 3, 9A - 9C, 14, 15, 16, 21

Supplementary Tables 1, 2, 3, 9A - 9C, 14, 15, 16, 21Supplementary Table 21 is the source data for figure 5<br>Supplementary Table legends: <b>Supplementary Table 1.</b> Distribution of samples with varying molecular characterization available for analysis.<b>Supplementary Table 2. </b>Association between genomic context, tumor type, grade with<b> A) </b>5-hmC MDI and <b>B) </b>5-mC MDI, determined by linear regression.<b>Supplementary Table 3</b>. Association between tumor purity, grade with <b>A)</b> 5-hmC MDI and <b>B)</b> 5-mC MDI, determined by linear regression.<b>Supplementary Table 9. A) </b>Annotation of gene name and genomic context of 28 dhmCpGs shared across tumor types. <b>B) </b>Proportion of shared dhmCpGs relative to CpG islands. <b>C) </b>Proportion of shared dhmCpGs in different genomic contexts.<b>Supplementary Table 14. </b>The number of differentially expressed genes with differentially hydroxymethylated CpGs identified by bulk tissue epigenome-wide association study. Categorized by the direction of gene expression change and the genomic context of the differentially hydroxymethylated CpGs for each tumor type.<b>Supplementary Table 15</b>. The number of nuclei from single nuclei RNA-seq that were included in the CellDMC analysis.<b>Supplementary Table 16. </b>The number of differentially hydroxymethylated CpGs per tumor type identified by CellDMC. Categorized by the change in the level of hydroxymethylation and cell type of association.<b>Supplementary Table 21. </b>Cell type-driven dhmCpGs and dmCpGs enrichment at genomic contexts.